| Target | cis/trans | Study | SNP | SNP location | Maj/min allele | MAF | N | βinv | seinv | Pinv | fclog | Plog | Praw |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Siglec-3 | cis | Discovery | rs1710354 | 19:51,802,140 | C/T | 0.38 | 996 | -0.387 | 0.043 | 2.3×10-18 | -1.180 | 6.5×10-20 | 5.6×10-18 |
| Siglec-3 | cis | Replication | rs1710354 | 19:51,802,140 | G/A | 0.24 | 337 | -0.251 | 0.074 | 0.001 | -1.130 | 3×10-4 | 0.001 |
| Target (abbrv.) | Siglec-3 |
| Target (full name) | Myeloid cell surface antigen CD33 |
| Somalogic ID (Sequence ID) | SL005215 (3166-92_1) |
| Entrez Gene Symbol | CD33 |
| UniProt ID | P20138 |
| UniProt Comment |
|
| Targeted by drugs (based on IPA annotation) |
|
| Biomarker applications (based on IPA annotation) |
|
All locus annotations are based on the sentinel SNP (rs1710354) and 1 proxy variant(s) that is/are in linkage disequilibrium r2 ≥ 0.8. Linkage disequilibrium is based on data from the 1000 Genomes Project, phase 3 version 5, European population and was retrieved using SNiPA's Block Annotation feature.
Download the detailed results of SNiPA's block annotation (PDF)